Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Should You Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s share price gapped up prior to trading on Friday . The stock had previously closed at $40.18, but opened at $42.50. Nanobiotix shares last traded at $41.5610, with a volume of 18,311 shares traded.

Analysts Set New Price Targets

NBTX has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Tuesday, April 21st. HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a research report on Monday. UBS Group increased their price objective on shares of Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Guggenheim increased their price objective on shares of Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, April 2nd. Finally, TD Cowen reissued a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $26.67.

Nanobiotix Trading Up 6.1%

The stock’s fifty day moving average is $35.69 and its two-hundred day moving average is $27.55.

Nanobiotix (NASDAQ:NBTX) last released its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The company had revenue of $3.42 million for the quarter. Equities analysts anticipate that Nanobiotix S.A. – Sponsored ADR will post 0.19 earnings per share for the current year.

Institutional Investors Weigh In On Nanobiotix

A number of large investors have recently added to or reduced their stakes in the company. Millennium Management LLC acquired a new stake in Nanobiotix during the 4th quarter valued at $390,000. Marshall Wace LLP acquired a new stake in Nanobiotix during the 4th quarter valued at $220,000. Optiver Holding B.V. acquired a new position in Nanobiotix during the 3rd quarter worth $101,000. Finally, Royal Bank of Canada grew its holdings in Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after acquiring an additional 2,500 shares in the last quarter. 38.81% of the stock is owned by institutional investors and hedge funds.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.